Study rationale and design of ADVANCE: action in diabetes and vascular disease--preterax and diamicron MR controlled evaluation.
AIMS/HYPOTHESIS: Patients with Type II (non-insulin-dependent) diabetes mellitus are at increased risk of macrovascular and microvascular disease, both of which are reduced by controlling raised blood pressure in hypertensive patients. Intensive glycaemic control has also been shown to reduce micro...
Main Author: | ADVANCE Management Committee |
---|---|
Format: | Journal article |
Language: | English |
Published: |
2001
|
Similar Items
-
Haemoglobin glycation index and risk for diabetes-related complications in the Action in Diabetes and Vascular Disease: Preterax and Diamicron Modified Release Controlled Evaluation (ADVANCE) trial
by: van Steen, S, et al.
Published: (2018) -
PROX1 gene CC genotype as a major determinant of early onset of type 2 diabetes in slavic study participants from Action in Diabetes and Vascular Disease: Preterax and Diamicron MR Controlled Evaluation study.
by: Hamet, P, et al.
Published: (2017) -
CT and MR angiography : comprehensive vascular assessment /
by: 394216 Rubin, Geoffrey D, et al.
Published: (2009) -
Aspirin for primary prevention of vascular disease in people with diabetes.
by: Haynes, R, et al.
Published: (2009) -
Hyperglycaemia induced immunomodulation of macrophages in diabetic vascular disease
by: Edgar, L
Published: (2019)